Cover Image

Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations

Soft-tissue sarcomas (STS) are a heterogeneous group of mesenchymal tumors for which response to immunotherapies is not well established. Therefore, it is important to risk-stratify and identify STS patients who will most likely benefit from these treatments.

Saved in:
Bibliographic Details
Main Authors: Simon, Malte (Author) , Mughal, Sadaf Shabbir (Author) , Horak, Peter (Author) , Uhrig, Sebastian (Author) , Buchloh, Jonas (Author) , Aybey, Bogac (Author) , Stenzinger, Albrecht (Author) , Glimm, Hanno (Author) , Fröhling, Stefan (Author) , Brors, Benedikt (Author) , Imbusch, Charles (Author)
Format: Article (Journal)
Language:English
Published: May 12 2021
In: Journal of translational medicine
Year: 2021, Volume: 19, Pages: 1-17
ISSN:1479-5876
DOI:10.1186/s12967-021-02858-7
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12967-021-02858-7
Get full text
Author Notes:Malte Simon, Sadaf S. Mughal, Peter Horak, Sebastian Uhrig, Jonas Buchloh, Bogac Aybey, Albrecht Stenzinger, Hanno Glimm, Stefan Fröhling, Benedikt Brors and Charles D. Imbusch
Description
Summary:Soft-tissue sarcomas (STS) are a heterogeneous group of mesenchymal tumors for which response to immunotherapies is not well established. Therefore, it is important to risk-stratify and identify STS patients who will most likely benefit from these treatments.
Item Description:Gesehen am 20.07.2021
Physical Description:Online Resource
ISSN:1479-5876
DOI:10.1186/s12967-021-02858-7

Similar Items